Our Team

Dieter Willbold

Dieter Willbold

Chairman of the Supervisory Board and Founder

Dieter Willbold studied biochemistry in Tübingen (Germany), Bayreuth (Germany) and Boulder (Colorado, USA). He completed his PhD in 1994 at the University of Bayreuth. After some more years in Bayreuth and a couple of research visits, e.g. at the Sackler School of Medicine of the Tel-Aviv University, he headed a junior research group at the Institute for Molecular Biotechnology in Jena. In 2001 Dieter Willbold became an associate Professor at the Heinrich-Heine-University of Düsseldorf. Since 2004, he is full professor at the Institute of Physical Biology at the Heinrich Heine University Düsseldorf. Since 2005, he is additionally director of the Institute of Complex Systems of the Research Centre Jülich.

Dagmar Jürgens

Dagmar Jürgens

Director Clinical Development and Founder

Dagmar Jürgens studied Agricultural Sciences at University of Göttingen (Germany) and subsequently earned her PhD at the University of Gießen. She gained experience at national and international levels since 1990, after founding and leading a small and medium-sized biotech enterprise for more than 15 years. In 2006 she changed her focus to Clinical Research and Drug Development. She furthered her experience in Phase II and III Clinical Trials, whilst working at the German Competent Authority (BfArM) and with international Contract Research Organizations. She has been working at the Jülich Research Center since 2011, first at the Technology Transfer Department, and then at the Institute of Complex Systems (ICS-6), where she is the Project Manager for Preclinical and Clinical Research.

Knut Adermann

Knut Adermann

Director CMC and Founder

Dr. Adermann has more than 20 years experience in peptide therapeutics discovery, translational medicine and clinical development, with a focus on the chemistry, manufacturing and control of novel, peptide active pharmacological ingredients. He holds a PhD in organic chemistry and has co-founded several biotech start-ups, pursuing indications in the fields of antivirals and antibacterials. He was involved in the successful sourcing of seed and round A financing for various start-up companies and has served as managing and scientific director of these ventures. As a consultant in peptide development, he has also supported various preclinical and clinical programs in cardiology, hematology and metabolic diseases.  He is an author of more than 90 publications and is a co-inventor of numerous internationally filed patents and patent applications.

Ralph Zahn

Ralph Zahn

Managing Director and Founder

Ralph Zahn holds a PhD in natural science from the University of Munich in cooperation with the Max-Planck-Institute for Biochemistry. He received a post-graduate doctors degree from Cambridge University and was for several years an Assistant Professor for Molecular Biology and Biophysics at the ETH Zurich. During his professional career, he was founder and Managing Director of BioSafety GmbH, co-founder and CEO of Alicon AG, a biotechnology enterprise in Zurich, CTO of Biocrates Life Sciences AG in Innsbruck, and Managing Director of Platomics GmbH in Vienna. In October 2014, Ralph Zahn founded Livenity GmbH in Zurich with the aim of marketing visionary technology products in the interface of Personalized Medicine, Digital Health, Bioinformatics and Artificial Intelligence.

Antje Willuweit

Antje Willuweit

Director Preclinical Research and Founder

Antje Willuweit studied Biology at the Technical University of Darmstadt (Germany) and received her PhD from the Max-Planck-Institute in Bad Nauheim (Germany). She gained 9 years of industrial experience in the following Biotech companies: Artemis Pharmaceuticals GmbH, Evotec Neurosciences AG, Evotec AG. In 2011 she joined the Jülich Research Centre at the Institute of Neuroscience and Medicine (INM-4), where she established her own research group. In total, she has got 20 years of experience with animal models in preclinical research, including at least 13 years in the field of preclinical drug testing against Alzheimer´s disease and other neurodegenerative diseases.

Gunther Kauselmann

Gunther Kauselmann

Director of Quality Management & Regulatory Compliance and Founder

Gunther Kauselmann studied Biology at the University of Hamburg and completed his PhD at the Center for Molecular Neuroscience Hamburg (ZMNH). In 1998 he joined the startup company Artemis Pharmaceuticals GmbH in Cologne, which was renamed Taconic Biosciences GmbH after being acquired by Taconic Biosciences Inc. in 2009. At Taconic Dr. Kauselmann held several management positions in scientific operations, quality management and regulatory compliance with increasing responsibility, before being appointed as Vice President of Operations to oversee the production process at the Cologne site. During his professional career he also graduated in Drug Regulatory Affairs and obtained his Master´s Certificate from the University of Bonn.